EAM Investors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

EAM Investors’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-223,654	Closed	-$2.79M	–	356
2022 Q3	$2.79M	Buy	+223,654	New	+$2.56M	0.61%	40
2019 Q3	–	Sell	-33,771	Closed	-$1.03M	–	309
2019 Q2	$1.03M	Buy	+33,771	New	+$711K	0.25%	188
2018 Q2	–	Sell	-98,551	Closed	-$3.65M	–	367
2018 Q1	$3.65M	Buy	+98,551	New	+$2.63M	0.61%	36

Other funds holding GTHX

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

EAM Investors's GTHX Position: Q4 2022 in Review

EAM Investors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2022, closing a stake of 223,654 shares — an estimated $2.79M sold.

EAM Investors first reported a position in GTHX in Q1 2018 and held it in 3 quarters. The position peaked at $3.65M in Q1 2018. 116 funds tracked by Wall St. Rank hold GTHX as of Q4 2022.

EAM Investors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
EAM Investors sold 223,654 G1 Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $2.79M.
EAM Investors first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
EAM Investors's G1 Therapeutics, Inc. Common Stock position peaked at $3.65M in Q1 2018.
116 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2022.

Based on EAM Investors's 13F filing for Q4 2022, filed 14 Feb 2023.